SCHEMBL203280

SCHEMBL203280

COc1ccc(-c2csc(COc3ccc(F)c(C(N)=O)c3F)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.59
POLB P06746 3/20 0.59
MEN1 O00255 6/20 0.57
PPARD Q03181 4/20 0.56
PPARA Q07869 2/20 0.56
RAB9A P51151 7/20 0.53
MAPT P10636 4/20 0.53
NPC1 O15118 5/20 0.47
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
OPRK1 P41145 1/20 0.47
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2707296 0.90 RAB9A (0.54) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL204423 0.89 L3MBTL1 (0.45) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL2705816 0.89 L3MBTL1 (0.53) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL2704589 0.89 PPARD (0.52) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL202833 0.88 POLB (0.53) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL2706162 0.88 HDAC3 (0.48) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL201521 0.87 PPARD (0.49) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL19471075 0.86 L3MBTL1 (0.42) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL19210500 0.86 L3MBTL1 (0.43) L3MBTL1POLBMEN1PPARDPPARA
SCHEMBL2707366 0.86 L3MBTL1 (0.55) L3MBTL1POLBMEN1PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20170305943-A1 COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TAXIS PHARMACEUTICALS, INC. (US) 2017-10-26 US disclosed
US-20170305943-A1 COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TAXIS PHARMACEUTICALS, INC. (US) 2017-10-26 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 L3MBTL1 703/4885POLB 364/4885MEN1 678/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 L3MBTL1 377/4885POLB 435/4885MEN1 1027/4885
US-20170305943-A1 COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS ELANE, MMP8, NISCH L3MBTL1 384/4885POLB 236/4885MEN1 3285/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 L3MBTL1 703/4885POLB 364/4885MEN1 678/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 L3MBTL1 703/4885POLB 364/4885MEN1 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.